<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02174419</url>
  </required_header>
  <id_info>
    <org_study_id>TR03</org_study_id>
    <secondary_id>2013-005627-17</secondary_id>
    <nct_id>NCT02174419</nct_id>
  </id_info>
  <brief_title>Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel, 3-Arm Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Prurigo Nodularis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trevi Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trevi Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of the study are to evaluate the effects of two doses of nalbuphine
      HCl ER tablets on the change from baseline in the worst itch Numerical Rating Scale (NRS) in
      patients with prurigo nodularis and to evaluate the safety and tolerability in the study
      population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline to the Evaluation Visit (Week 10) in itch on the 0-10 Numerical Rating Scale</measure>
    <time_frame>Baseline, Week 10</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to the Evaluation Visit (Week 10) in the mean itch on the 0-10 Numerical Rating Scale</measure>
    <time_frame>Baseline, Week 10</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from Baseline to the Evaluation Visit (Week 10) in the Verbal Rating Scale</measure>
    <time_frame>Baseline, Week 10</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Prurigo Nodularis</condition>
  <condition>Nodularis Prurigo</condition>
  <condition>Prurigo</condition>
  <condition>Pruritus</condition>
  <arm_group>
    <arm_group_label>nalbuphine HCl ER 90mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nalbuphine HCl ER tablets 90 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nalbuphine HCl ER 180 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nalbuphine HCl ER tablets 180 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nalbuphine HCl ER tablets 90 mg BID</intervention_name>
    <description>nalbuphine HCl ER tablets 90 mg BID administered for 8 weeks</description>
    <arm_group_label>nalbuphine HCl ER 90mg</arm_group_label>
    <other_name>nalbuphine ER</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nalbuphine HCl ER tablets 180 mg BID</intervention_name>
    <description>nalbuphine HCl ER tablets 180 mg BID administered for 8 weeks</description>
    <arm_group_label>nalbuphine HCl ER 180 mg</arm_group_label>
    <other_name>nalbuphine ER</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablets BID</intervention_name>
    <description>Placebo tablets BID administered for 10 weeks</description>
    <arm_group_label>Sugar pill</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject suffering from generalized prurigo nodularis

          -  Have demonstrated pruritus intensity during screening

          -  Male or female who are at least 18 years old at the time of consent

        Exclusion Criteria:

          -  Subject has chronic pruritus resulting from other conditions

          -  Subject has a history of substance abuse within the past year

          -  Subject has a known drug allergy to opioids

          -  Subject is a pregnant or lactating female
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Sciascia, MD</last_name>
    <role>Study Director</role>
    <affiliation>Trevi Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Münster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wroclawiu</name>
      <address>
        <city>Wroclaw</city>
        <state>Dolnoslaskie</state>
        <zip>50-368</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2014</study_first_submitted>
  <study_first_submitted_qc>June 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2014</study_first_posted>
  <disposition_first_submitted>May 25, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>May 25, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">June 6, 2017</disposition_first_posted>
  <last_update_submitted>May 25, 2017</last_update_submitted>
  <last_update_submitted_qc>May 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Itch</keyword>
  <keyword>Chronic Itch</keyword>
  <keyword>nalbuphine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pruritus</mesh_term>
    <mesh_term>Prurigo</mesh_term>
    <mesh_term>Neurodermatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nalbuphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

